InMed Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $13.36 Mil.
During the past 12 months, InMed Pharmaceuticals's average Total Assets Growth Rate was 12.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 38.50% per year.
During the past 5 years, the average Total Assets Growth Rate was 42.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 59.70% per year.
During the past 13 years, InMed Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 972.90%. The lowest was -80.60%. And the median was 1.35%.
InMed Pharmaceuticals Total Assets Historical Data
The historical data trend for InMed Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
InMed Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (NAS:INM) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
InMed Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
InMed Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of InMed Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
InMed Pharmaceuticals (InMed Pharmaceuticals) Business Description
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INM has been successfully added to your 